• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Endotypes of Severe Asthma: 5 Questions on Pathways, Biomarkers, Biologics

Slideshow

Key factors in choosing appropriate biologic therapy for a patient with severe asthma include consideration of the specific mechanistic pathway that underlies the presentation, investigation of biomarker levels, and evaluation of comorbid inflammatory disease.

Following are 5 questions on these topics that are based on a comprehensive review and international expert opinion published in the Journal of Allergy and Clinical Immunology: In Practice by a group of clinicians recognized internationally for knowledge of severe asthma and of biologic medications. Test your endotype IQ.


Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
© 2024 MJH Life Sciences

All rights reserved.